<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03715153</url>
  </required_header>
  <id_info>
    <org_study_id>CL3-95008-002</org_study_id>
    <secondary_id>2017-004420-30</secondary_id>
    <nct_id>NCT03715153</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.</brief_title>
  <official_title>Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder. A 6-month Randomised, Double-blind, Placebo Controlled Multicentre Parallel Group Study to Evaluate Efficacy and Safety of Bumetanide 0.5mg Twice a Day Followed by an Open Label Active 6-month Treatment Period With Bumetanide (0.5mg Twice a Day) and a 6 Weeks Discontinuation Period After Treatment Stop.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ADIR, a Servier Group company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacity and the safety of bumetanide/S95008
      in the improvement of Autism Spectrum Disorder core symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study (CL3-95008-002) will be performed in children from 2 to less than 7 years
      old presenting with ASD. A 6-month double-blind treatment period will be performed in which
      efficacy and safety of bumetanide 0.5mg BID will be assessed versus placebo. This
      double-blind period will be followed by a 6-month open label treatment period of bumetanide
      0.5mg BID in which long term safety will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2018</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>6-month, randomized, double-blind, placebo-controlled, parallel groups followed by an open label active 6-month treatment period with bumetanide.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Childhood Autism Rating Scale, Second Edition (CARS2) total raw score</measure>
    <time_frame>change from baseline to 6 month</time_frame>
    <description>Efficacy criterion The CARS2 is a 15 item rated instrument. The rating values given for the 15 areas are summed to produce a Total score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Social Responsiveness Scale, Second Edition (SRS-2) total raw score</measure>
    <time_frame>Change from baseline to 6 month</time_frame>
    <description>Efficacy criterion 65 items scale measuring symptoms associated with autism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Global Improvement (CGI-I) score</measure>
    <time_frame>At 6 months</time_frame>
    <description>Efficacy criterion Scale which assesses the severity of the illness and the global improvement of the patient Under study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vineland Adaptative Behaviour Scale II (VABS II)</measure>
    <time_frame>Change from baseline to 6 month</time_frame>
    <description>Efficacy criterion Scale designated to measure adaptative behaviour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event and Pediatric Adverse Event Rating Scale (PAERS)</measure>
    <time_frame>On average of 52 weeks</time_frame>
    <description>Safety criterion Inventory report used to identify signs/symptoms experienced by the patient since the study treatment initiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormalities in 12-leads electrocardiogram (ECG) parameters</measure>
    <time_frame>Selection visit, Week004, Week008, Week012, Week026, Week030, Week034, Week038, Week052</time_frame>
    <description>Safety criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal ultrasound</measure>
    <time_frame>Selection visit, Week026, Week052</time_frame>
    <description>Safety criterion Assessment of the renal function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia-Suicide severity scale Children's version (C-SSRS-C)</measure>
    <time_frame>Week000/Week012/Week026/Week038/Week052</time_frame>
    <description>Scale which assesses suicidal ideation and suicidal behaviour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability and palatability questionnaires</measure>
    <time_frame>Week026</time_frame>
    <description>Acceptability and palatability criterion Assessment of the ease of use to use the dosing device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paediatric Quality of Life Inventory (PedsQL) questionnaire</measure>
    <time_frame>Week000/Week004/Week012/v026/Week030/Week038/Week052</time_frame>
    <description>Quality of Life questionnaire Assessment of parent/legal representative perception of patient health related quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Autism Spectrum Disorder (ASD)</condition>
  <arm_group>
    <arm_group_label>BUMETANIDE/S95008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BUMETANIDE/S95008</intervention_name>
    <description>Oral solution dosed at 0.5 mg/mL Taken twice daily.</description>
    <arm_group_label>BUMETANIDE/S95008</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Oral solution Taken twice daily.</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients from 2 to less than 7

          -  Primary diagnosis of ASD as per Diagnostic and Statistical Manual of Mental Disorders
             - Fifth Edition (DSM-5) criteria

          -  Criteria met for ASD on Autism Diagnostic Observation Schedule-Generic (ADOS-2) and
             Autism Diagnosis Interview Revised (ADI-R)

          -  CGI (Clinical Global Impression) - Severity rating Score ≥ 4

          -  Childhood Autism Rating Scale second edition (CARS2-ST or HF) total raw score ≥ 34

          -  Social responsiveness Scale second edition (SRS-2) total score ≥ 66 T-Score

          -  Absence of diagnosis of Fragile X or Rett Syndrome

          -  Absence of any clinically significant abnormality likely to interfere with the conduct
             of the study according to the judgment of the investigator.

        Exclusion Criteria:

          -  Patients not able to follow the study assessments defined by the protocol, with the
             exception of self-rating questionnaires which will be assessed by parent/legal
             representative/caregiver for those patients unable to complete them

          -  Patients having a high suicidal risk according to the investigator judgement

          -  Chronic renal dysfunction

          -  Chronic cardiac dysfunction

          -  Patient with unstable psychotherapy, behavioural, cognitive or cognitive-behavioural
             therapy

          -  Severe electrolyte imbalance that is likely to interfere with the study conduct or
             evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Institut de Recherches Internationales Servier Clinical Studies Department</last_name>
    <phone>+33 1 55 72 43 66</phone>
    <email>clinical.trial.management@servier.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Psychiatry and Behavioral Medicine</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+61 491 619 216</phone>
      <email>a.k.montgomery@unsw.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Children's Hospital Melbourne</name>
      <address>
        <city>Parkville</city>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>kylie.crompton@mcri.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trial Tech em Pesquisas com Medicamentos Ltda</name>
      <address>
        <city>Curitiba</city>
        <zip>80240-280</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>lfpetry@yahoo.com.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Walter Cantídio-Universidade Federal do Ceará</name>
      <address>
        <city>Fortaleza</city>
        <zip>60430-370</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jibiapinaneto@yahoo.com.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Neurológica e Neurocirúrgica de Joinville</name>
      <address>
        <city>Joinville</city>
        <zip>89202-190</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+55 47 3451-2596</phone>
      <email>carlahcmoro@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital São Vicente de Paulo</name>
      <address>
        <city>Passo Fundo</city>
        <zip>99010-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>cmforcelini@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de São Paulo, Escola Paulista de Medicina</name>
      <address>
        <city>São Paulo</city>
        <zip>04017-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jamari17@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina da Universidade de São Paulo - Departamento de psiquiatra</name>
      <address>
        <city>São Paulo</city>
        <zip>054030-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Brentani</last_name>
      <phone>55 11 2661-6978</phone>
      <email>helena.brentani@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University hospital of Ostrava, Department of Psychiatry</name>
      <address>
        <city>Poruba</city>
        <state>Ostrava</state>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+4 2 0597373280</phone>
      <email>jan.uhlir@fno.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno, Department of Child Neurology</name>
      <address>
        <city>Brno</city>
        <zip>613 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>danhofer.pavlina@fnbrno.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Neuropsychiatric Care, Department of Child Psychiatry</name>
      <address>
        <city>Praha</city>
        <zip>186 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+4 2 0739226131</phone>
      <email>clinicaltrials@inep.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GSC CHU-LENVAL Centre ressource autisme</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>6200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Serret</last_name>
      <phone>+33 04 92 03 04 39</phone>
      <email>serret.s@pédiatrie-chulenval-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg Service de Psychiatrie de l'Enfant et de l'Adolescent</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace-Champagne-Ardenne-Lorraine</state>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Ohresser</last_name>
      <phone>+33 3 88 11 52 48</phone>
      <email>isabelle.ohresser@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique de Lyon</name>
      <address>
        <city>Bron</city>
        <state>Auvergne Rhone Alpes</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>sandrine mardirossian</last_name>
      <email>sandrine.mardirossian@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Le Vinatier CRA Rhône-Alpes, Bat 211</name>
      <address>
        <city>Bron Cedex</city>
        <state>Auvergne-Rhône-Alpes</state>
        <zip>69678</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine Mardirossian</last_name>
      <email>sandrine.mardirossian@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré Service de Psychiatrie de l'enfant et de l'adolescent</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard DELORME</last_name>
      <phone>+33 1 40 03 23 00</phone>
      <email>richard.delorme.rdb@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <state>Normandie</state>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Mestre</last_name>
      <phone>02 32 88 57 84</phone>
      <email>Nathalie.Mestre@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Rouvray Centre de Ressources pour l'Autisme</name>
      <address>
        <city>Sotteville-lès-Rouen</city>
        <state>Normandie</state>
        <zip>76301</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Mestre</last_name>
      <phone>+33 2 32 88 57 84</phone>
      <email>Nathalie.Mestre@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital des Enfants-Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <state>Nouvelle Aquitaine</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Bouvard</last_name>
      <phone>+33 5.57.82.02.04</phone>
      <email>mbouvard@ch-perrens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Charles Perrens CRA Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <state>Nouvelle-Aquitaine</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel BOUVARD</last_name>
      <phone>+33 5 56 56 17 19</phone>
      <email>mbouvard@ch-perrens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Zentrum für Psychische Erkrankungen, Klinik für Psychiatrie, Psychotherapie und Psychosomatik im Kindes- und Jugendalter</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters am Zentralinstitut für Seelische Gesundheit</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Abt. Psychiatrie, Psychosomatik und Psychotherapie im Kindes- und Jugendalter</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der TU Dresden, Klinik und Poliklinik für Kinder- und Jugendpsychiatrie und-psychotherapie</name>
      <address>
        <city>Dresden</city>
        <state>Saxony (Sachsen)</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Vadaskert Korhaz es Szakambulancia</name>
      <address>
        <city>Budapest</city>
        <zip>1021</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Péter Nagy</last_name>
      <phone>+36 1 392 1400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Servus Salvus Fft.</name>
      <address>
        <city>Budapest</city>
        <zip>1026</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Altmann</last_name>
      <email>altmann.anna@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Magyar Református Egyház Bethesda Gyermekkórháza</name>
      <address>
        <city>Budapest</city>
        <zip>1143</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz Gyermek es ifjusagpszichiatriai osztaly</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdolna Gácser</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudományegyetem Szent-Gyorgy Albert Klinikai Kozpont Gyermekgyógyászati Klinika Gyermek es Ifjusagpszichiátriai o</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krisztina Kapornai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neuro Riabilitazione/Psicopatologia dell'età evolutiva Istituto Scientifico Medea - Bosisio Parini</name>
      <address>
        <city>Bosisio Parini</city>
        <state>Lombardia</state>
        <zip>23842</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+39 031 877584</phone>
      <email>ambulatorio.psicofarmacologia@lanostrafamiglia.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. di Neuropsichiatria Infantile Fondazione Istituto Neurologico Nazionale Casimiro Mondino Istituto di Ricovero e Cura a Carattere Scientifico</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Maria Mensi</last_name>
      <phone>+39 0382 380242</phone>
      <email>martina.mensi@mondino.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica di Neuropsichiatria dell'Infanzia e dell'Adolescenza Ospedale Pediatrico-Microcitemico</name>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Medda</last_name>
      <phone>+39 070 52963512</phone>
      <email>caterina.medda@unica.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Programma Interdipartimentale &quot;Autismo 0-90&quot; A.O.U. Policlinico &quot;Gaetano Martino&quot;</name>
      <address>
        <city>Messina</city>
        <state>Sicilia</state>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>U.O.C. Psichiatria dello Sviluppo IRCCS Fondazione Stella Maris</name>
      <address>
        <city>Calambrone</city>
        <state>Toscana</state>
        <zip>56128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Santocchi</last_name>
      <phone>+39 050 88 63 13</phone>
      <email>e.santocchi@fsm.unipi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. di Neuropsichiatria Infantile Azienda Ospedaliera Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <state>Toscana</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Canitano</last_name>
      <email>canitano@unisi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Niepubliczny Zakład Opieki Zdrowotnej Gdańskie Centrum Zdrowia Sp. z o.o.</name>
      <address>
        <city>Gdansk</city>
        <zip>80-542</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+ 48 58 342-34-08</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Badań Klinicznych PI-House sp. z o.o</name>
      <address>
        <city>Gdansk</city>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48 58 719 22 22</phone>
      <email>pihouse@pihouse.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NAVICULA Centrum Diagnozy i Terapii Autyzmu w Łodzi</name>
      <address>
        <city>Lodz</city>
        <zip>91-126</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+(48)42-611-83-45</phone>
      <email>centrum@navicula.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacja SYNAPSIS ul.</name>
      <address>
        <city>Warszawa</city>
        <zip>02-085</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48 22 825-87-42</phone>
      <email>badaniakliniczne2@synapsis.org.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Dziecięcy Szpital Kliniczny w Warszawie Oddział Kliniczny Psychiatrii Wieku Rozwojowego</name>
      <address>
        <city>Warszawa</city>
        <zip>02-091</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+(48) 22 317 92 51</phone>
      <email>psychiatria@spdsk.edu.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar e Universitario de Coimbra Hospital Pediatrico</name>
      <address>
        <city>Coimbra</city>
        <zip>300-062</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guiomar Oliveira</last_name>
      <phone>+ 351 96 554 7899</phone>
      <email>guiomar@chuc.min-saude.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institute of Children Diseases, Department of Child Psychiatry</name>
      <address>
        <city>Bratislava</city>
        <zip>833 40</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+42 1 259371508</phone>
      <email>studiaoautizme@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>EPAMED, s.r.o.</name>
      <address>
        <city>Košice</city>
        <zip>040 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospita Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amaia Hervas</last_name>
      <email>ahervas@mutuaterrassa.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinica Guipuzcoa</name>
      <address>
        <city>San Sebastian</city>
        <state>Guipuzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inmaculada Palanca</last_name>
      <email>farmacologia_clinica@idiphim.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Usm Infantil Benalua</name>
      <address>
        <city>Alicante</city>
        <zip>03007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Auxiliadora Javaloyes</last_name>
      <email>javaloyes_marsan@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa María Calvo Escalona</last_name>
      <phone>00 34 93 227 54 00</phone>
      <phone_ext>4212</phone_ext>
      <email>maredondo@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Niño Jesus</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Gutierrez Priego</last_name>
      <phone>00 34 91 5035900</phone>
      <phone_ext>351</phone_ext>
      <email>silvia.gutierrezp@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colchester Hospital</name>
      <address>
        <city>Colchester</city>
        <zip>CO4 5JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 (0)120 6746 285</phone>
      <email>synapse@esneft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ReCognition Health</name>
      <address>
        <city>London</city>
        <zip>W1G 9JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Winnicott Centre 195-197 Hathersage Road</name>
      <address>
        <city>Manchester</city>
        <zip>M13 0JE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.servier.com/</url>
    <description>Find Results on Servier Clinical Trial Data website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 12, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bumetanide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.
They can ask for all interventional clinical studies:
submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new médicine (or the new indication) in one of the EEA Member States will be considered within this scope.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After Marketing Authorisation in EEA or US if the study is used for the approval.</ipd_time_frame>
    <ipd_access_criteria>Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.</ipd_access_criteria>
    <ipd_url>http://clinicaltrials.servier.com/</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>study-level clinical trial data]</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

